ReviewChest2021
Protein Biomarkers for COPD Outcomes.
Review in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 92 citations in OpenAlex.
- Plasma metabolomic signatures enable the diagnosis and prognosis of chronic obstructive pulmonary disease.Nature communications · 2026Article
- Plasma proteomic profiling uncovers the age-related molecular changes in chronic obstructive pulmonary disease.BMC pulmonary medicine · 2026Article
- Circulating proteomic landscape of lung function.The European respiratory journal · 2026Article
- Dyspnea in Chronic Obstructive Pulmonary Disease: Expert Assessment of Management in Clinical Practice.Pulmonary therapy · 2025Article
- Beyond the Critical Threshold: Elastic Fiber Remodeling and Fracture in the Pathogenesis of Pulmonary Emphysema.International journal of molecular sciences · 2025Review
- Exposome and the Prevention of Lung Diseases: A New Paradigm for Lung Health and Prevention.Thoracic research and practice · 2025Article
- The higher serum uric acid to high-density lipoprotein cholesterol ratio is associated with increased risk of chronic obstructive pulmonary disease: result from NHANES 2011-2018.BMC pulmonary medicine · 2025Article
- Asthma and extrapulmonary comorbidities in a middle-aged general population: results from the SCAPIS study.BMJ open respiratory research · 2025Article
- Decoding mechanisms and protein markers in lung-brain axis.Respiratory research · 2025Review
- The Emerging Biomarkers in Chronic Obstructive Pulmonary Disease: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Multi-omics characterization of early chronic obstructive pulmonary disease.Respiratory research · 2025Article
- DNA methylation-predicted plasma protein levels and breast cancer risk.Breast cancer research : BCR · 2025Article
- Correlation between the body roundness index and chronic obstructive pulmonary disease: a cross-sectional analysis.Frontiers in nutrition · 2025Article
- Association Between Blood Urea Nitrogen to Serum Albumin Ratio and Mortality in Critically Ill Patients With Chronic Obstructive Pulmonary Disease: A Retrospective Study.International journal of chronic obstructive pulmonary disease · 2025Article
- COPD is associated with increased cardiovascular disease risk independent of phenotype.Respirology (Carlton, Vic.) · 2024Article
- Therapeutic potential of β-hydroxybutyrate in the management of pancreatic neoplasms: exploring novel diagnostic and treatment strategies.Lipids in health and disease · 2024Review
- Comprehensive comorbidity assessment for the ECOPD: a long-term multi-centre retrospective study.BMC pulmonary medicine · 2024Article
- Proteomic networks and related genetic variants associated with smoking and chronic obstructive pulmonary disease.BMC genomics · 2024Article
- Review
- Dynamic and prognostic proteomic associations with FEVmedRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
COPD is a clinically heterogeneous syndrome characterized by injury to airways, airspaces, and lung vasculature and usually caused by tobacco smoke and/or air pollution exposure. COPD is also independently associated with nonpulmonary comorbidities (eg, cardiovascular disease) and malignancies (eg, GI, bladder), suggesting a role for systemic injury. Since not all those with exposure develop COPD, there has been a search for plasma and lung biomarkers that confer increased cross-sectional and longitudinal risk. This search typically focuses on clinically relevant COPD outcomes such as FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.